NovoCure director receives new share and option awards

NovoCure Ltd director Vernon W. Anthony reported equity compensation awards.

Rhea-AI Filing Summary

NovoCure Ltd director Vernon W. Anthony reported equity compensation awards. He received 11,610 ordinary shares in the form of restricted stock units that vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding the company’s 2027 annual general meeting of shareholders. He also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest and become exercisable on the same schedule and expire on June 3, 2036. Following these awards, he holds 209,267 ordinary shares directly.

Insider Trade Summary

Grant/Award: 28,609 shares

Grant/Award 2 txns

Insider VERNON W ANTHONY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,999	$0.00	$0.00
Grant/Award	Ordinary Shares	11,610	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 16,999 contracts (Direct); Ordinary Shares — 209,267 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
2. F2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Key Figures

RSUs granted: 11,610 units Options granted: 16,999 options Option exercise price: $16.15 per share +2 more

5 metrics

RSUs granted 11,610 units Restricted stock units granted June 3, 2026

Options granted 16,999 options Stock options granted June 3, 2026

Option exercise price $16.15 per share Exercise price for new stock options

Shares held after grant 209,267 shares Ordinary shares directly held post-award

Option expiration June 3, 2036 Expiration date for new stock options

Key Terms

restricted stock units, Stock Option (Right to Buy), vest, annual general meeting of shareholders

4 terms

restricted stock units financial

"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with underlying ordinary shares and an exercise price"

vest financial

"are scheduled to vest 100% on the earlier of the following dates"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

annual general meeting of shareholders financial

"the day immediately preceding the Company's 2027 annual general meeting of shareholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NovoCure (NVCR) director Vernon W. Anthony report in this Form 4?

Vernon W. Anthony reported equity compensation awards, not open-market trades. He received restricted stock units and stock options on NovoCure ordinary shares, reflecting routine director compensation rather than a discretionary purchase or sale in the market.

How many NovoCure (NVCR) restricted stock units were granted to Vernon W. Anthony?

He was granted 11,610 restricted stock units tied to NovoCure ordinary shares. These units represent share-based compensation that will convert into shares when they vest, subject to the specified vesting schedule and his continued service on the board.

What stock options did Vernon W. Anthony receive from NovoCure (NVCR)?

He received stock options covering 16,999 ordinary shares with an exercise price of $16.15 per share. These options give him the right to buy NovoCure shares at that price once they vest and become exercisable under the award terms.

When do the new NovoCure (NVCR) restricted stock units for Vernon W. Anthony vest?

The restricted stock units vest 100% on the earlier of two dates: the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders, aligning vesting with the company’s board cycle.

What is the vesting and expiration schedule for Vernon W. Anthony’s NovoCure (NVCR) stock options?

The options fully vest and become exercisable on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual meeting. They have a long-term expiration date of June 3, 2036, providing extended exercise flexibility.

How many NovoCure (NVCR) shares does Vernon W. Anthony hold after these awards?

After the reported grant of restricted stock units, Vernon W. Anthony directly holds 209,267 NovoCure ordinary shares. This figure reflects his post-transaction position as disclosed and shows his ongoing equity exposure as a member of the company’s board.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VERNON W ANTHONY

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/03/2026		A		11,610	A	$0.00	209,267	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.15	06/03/2026		A		16,999		06/03/2027(2)	06/03/2036	Ordinary Shares	16,999	$0.00	16,999	D

Explanation of Responses:

1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Remarks:

	Steven Robbins, as attorney in fact for Vernon, W. Anthony	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)